查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552564

癌症基因治療市場規模、佔有率和趨勢分析報告：按治療、按最終用途、按地區、細分市場預測，2024-2030年

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

癌症基因治療市場的成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球癌症基因治療市場預計將達到 127.6 億美元。

由於全球對新療法的需求不斷增加以及全球癌症發生率不斷上升，預計 2024 年至 2030 年該市場的複合年成長率將達到 18.9%。而且，該治療方法為各類遺傳性和誘發性癌症提供了絕對的解決方案，使其成為作為癌症治療藥物更理想的選擇。例如，Kite 的 Tecartus (brexucabtagene autoleucel) 已獲得 FDA核准用於治療復發性或難治性 B 細胞前驅急性淋巴細胞白血病。

惡性的盛行率在全球範圍內不斷增加，預計這將推動對有效治療和各種策略的需求，以應對日益增加的惡性發病率。此外，市場的技術進步預計將為新型療法提供新的機會。因此，產品核准的數量正在增加。例如，2022年3月，歐洲醫療機構建議給予Carvykti（ciltacabtagene autoleucel）有條件行銷核准，用於治療復發性和難治性多發性骨髓瘤。

該市場受到世界各國政府和國家癌症協會的積極支持的積極推動。人們越來越關注增加癌症基因治療的研究經費。例如，2021 年 12 月，荷蘭平台 DARE-NL（荷蘭）獲得了 KWF 荷蘭癌症協會 520 萬美元的津貼。這筆津貼將使 DARE-NL 能夠推進針對貧困人群的細胞和基因治療策略。

亞洲製造商專注於可大量生產的較不複雜的分子，因此對新的複雜技術的投資相對較少。因此，投資高產量、低成本技術是歐洲和北美等其他已開發地區製造商避免競爭壓力的一種選擇。

市場上營運的主要公司都專注於開發強大的癌症基因治療藥物的合作研究。例如，2022年8月，Gensaic與Ovid Therapeutics達成合作研究協議，利用專有的噬菌體衍生粒子基因治療平台開發多達三種中樞神經系統適應症的基因藥物。

癌症基因治療市場報告亮點

  • 隨著對基因層面上癌症病理學認知的進步以及對基因誘導免疫療法和個人化醫療的需求的增加，市場正處於一個重要的轉折點。
  • 由於基因誘導免疫治療研究的進展，2023年基因誘導免疫治療領域佔最大市場。
  • 由於對新型基因療法的需求不斷成長以及 FDA核准癌症基因療法的數量不斷增加，生物製藥公司在 2023 年佔據了最大的市場佔有率。由於該領域研發活動的增加，生物製藥公司預計在預測期內將成長最快。
  • 由於關鍵參與者的存在以及政府和國家癌症研究所加強支持以推進該地區的癌症研究，北美將在 2023 年佔據市場主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章癌症基因治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 癌症基因治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章癌症基因治療市場：依治療方法估算與趨勢分析

  • 細分儀表板
  • 癌症基因治療市場：治療波動分析
  • 癌症基因治療市場：依治療分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 溶瘤病毒療法
  • 基因誘導的免疫治療
  • 基因轉移

第5章癌症基因治療市場：依最終用途的估計和趨勢分析

  • 細分儀表板
  • 癌症基因治療市場：最終用途變異分析
  • 癌症基因治療市場：依最終用途分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 建築機構
  • 生物製藥公司
  • 診斷中心
  • 其他

第6章癌症基因治療市場：按治療方法和最終用途分類的區域估計和趨勢分析

  • 區域儀表板
  • 癌症基因治療市場：區域差異分析
  • 癌症基因治療市場：按技術和最終用途進行區域估計和趨勢分析
  • 2018-2030年市場規模、預測及趨勢分析
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他國家

第7章 競爭格局

  • 市場參與企業分類
  • 主要企業簡介
    • Abeona Therapeutics Inc.
    • Asklepios BioPharmaceutical Inc.
    • Altor Bioscience Inc.
    • Bluebird bio Inc.
    • BioCancell Inc.
    • CelgeneInc.
    • Elevate BioInc.
    • GlaxoSmithKlineInc.
    • Genelux Corporation
    • GenVec
    • Introgen TherapeuticsInc.
    • OncoGenex Pharmaceuticals Inc.
Product Code: GVR-4-68039-984-2

Cancer Gene Therapy Market Growth & Trends:

The global cancer gene therapy market size is expected to reach USD 12.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.9% from 2024 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform.

Cancer Gene Therapy Market Report Highlights:

  • The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine
  • The gene induced immunotherapy segment held the largest share in 2023 due to increase in the advancement in gene induced immunotherapy research
  • Biopharmaceutical companies held the largest market share in 2023 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field
  • North America dominated the market in 2023 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Gane Therapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. High growth of the pharmaceutical industry
      • 3.2.1.2. Rising R&D investments and demand for novel cancer therapeutics
      • 3.2.1.3. Increased incidence of cancers
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High product prices
      • 3.2.2.2. Unethical use of gene therapy
  • 3.3. Cancer Gene Therapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cancer Gane Therapy Market: Therapy Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Gene Therapy Market: Therapy Movement Analysis
  • 4.3. Cancer Gene Therapy Market by Therapy Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Oncolytic Virotherapy
    • 4.5.1. Oncolytic Virotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Gene Induced Immunotherapy
    • 4.6.1. Gene Induced Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Gene Transfer
    • 4.7.1. Gene Transfer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cancer Gene Therapy Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Cancer Gene Therapy Market: End Use Movement Analysis
  • 5.3. Cancer Gene Therapy Market by End Use Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Research Institutes
    • 5.5.1. Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Biopharmaceutical Companies
    • 5.6.1. Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Diagnostic Centers
    • 5.7.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Therapy and End Use

  • 6.1. Regional Dashboard
  • 6.2. Regional Cancer Gene Therapy Market Movement Analysis
  • 6.3. Cancer Gene Therapy Market: Regional Estimates & Trend Analysis by Technology & End Use
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. North America
    • 6.5.1. North America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement scenario
      • 6.5.2.5. U.S. Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement scenario
      • 6.5.3.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement scenario
      • 6.5.4.5. Canada Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. UK
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement scenario
      • 6.6.2.5. UK Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement scenario
      • 6.6.3.5. Germany Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Switzerland
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement scenario
      • 6.6.4.5. Switzerland Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Japan
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement scenario
      • 6.7.2.5. Japan Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement scenario
      • 6.7.3.5. China Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. Reimbursement scenario
      • 6.7.4.5. Australia Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Rest of World
    • 6.8.1. Latin America Cancer Gene Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Key Company Profiles
    • 7.2.1. Abeona Therapeutics Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Asklepios BioPharmaceutical Inc.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Altor Bioscience Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Bluebird bio Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. BioCancell Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. CelgeneInc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Elevate BioInc.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. GlaxoSmithKlineInc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Genelux Corporation
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. GenVec
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Introgen TherapeuticsInc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. OncoGenex Pharmaceuticals Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 Global cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 North America cancer gene therapy market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 North America cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 9 U.S. cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 Canada cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Mexico cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 13 Mexico cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 16 Europe cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 UK cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 18 UK cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Germany cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 20 Germany cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 Switzerland cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 Switzerland cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific cancer gene therapy market, by country, 2018 - 2030 (USD Million)
  • Table 24 Asia Pacific cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 25 Asia Pacific cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Japan cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 27 Japan cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 China cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 29 China cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Australia cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 31 Australia cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Rest of World cancer gene therapy market, by therapy, 2018 - 2030 (USD Million)
  • Table 33 Rest of World cancer gene therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement Primary Research Pattern
  • Fig. 2 Market Research Approaches
  • Fig. 3 Value Chain-Based Sizing & Forecasting
  • Fig. 4 Market Formulation & Validation
  • Fig. 5 Market driver analysis
  • Fig. 6 Market restraint analysis
  • Fig. 7 PESTEL Analysis
  • Fig. 8 Porter's Five Forces Analysis
  • Fig. 9 Cancer gene therapy market, therapy outlook key takeaways (USD Million)
  • Fig. 10 Cancer gene therapy market: Therapy movement analysis 2023 & 2030 (USD Million)
  • Fig. 11 Oncolytic Virotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 12 Gene induced immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Gene transfer market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Cancer gene therapy market, end use outlook key takeaways (USD Million)
  • Fig. 15 Cancer gene therapy market: End use movement analysis (USD Million), 2023 & 2030
  • Fig. 16 Research institutes market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Biopharmaceutical companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Diagnostic centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Cancer gene therapy market: Regional key takeaways (USD Million)
  • Fig. 21 Cancer gene therapy market: regional outlook, 2023 & 2030 (USD Million)
  • Fig. 22 North America cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Switzerland cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Asia Pacific cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 China cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Japan cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Australia cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Rest of World cancer gene therapy market estimates and forecasts, 2018 - 2030 (USD Million)